AP-03

N/A

Report date: 2026/01/04 17:56:01

Base Information

Drug NameAP-03
Drug Alias NamesiRNA delivering mAb targeting MIR-03 (Antapodia Nanotherapeutics)Antapodia 03AP-03
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionMetastasis inhibitors
TargetsUpdating
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAntapodia Nanotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAntapodia Nanotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A